Perrigo Co Plc Stock Price, News & Analysis

Perrigo (NYSE:PRGO), through its Good Start® | Dr. Brown's™ brand, has announced a nationwide giveaway contest starting July 1, 2025. The month-long contest will select 100 winners who will each receive a two-month supply of Gentle Pro™ baby formula along with Dr. Brown's products, valued at $516.49 per winner.

Alongside the contest, the company is making a significant charitable contribution to Baby2Baby, donating over 4,000 cans of Gentle Pro™ formula plus Dr. Brown's products, supporting over 95,000 feedings with a total donation value exceeding $85,000. The combined contest and donation initiative has an approximate retail value of $139,071.

The contest runs through July with winners to be announced by August 6th. Gentle Pro™, described as the company's closest formula to breastmilk, features gut-friendly probiotics and 100% whey proteins, designed for babies with sensitive tummies.

Perrigo (NYSE: PRGO) announced a leadership transition in its global operations and supply chain, with Matt Winterman appointed as Executive Vice President, Product Supply, Operations Strategy and Transformation Officer, effective June 23, 2025. He succeeds Ron Janish, who will retire on September 30, 2025, after over 20 years with the company. Winterman brings more than 20 years of experience, most recently serving as SVP of Global Supply Chain and Strategy at AstraZeneca, where he managed a $54 billion supply chain across 5,000 SKUs. Janish's tenure was marked by significant achievements in supply chain transformation and maintaining operational resilience during COVID-19. The transition will involve both executives working together to ensure continuity in Perrigo's operations and advancement of its consumer self-care strategy.

Perrigo (NYSE: PRGO), a leading provider of Consumer Self-Care Products, announced that CEO Patrick Lockwood-Taylor and CFO Eduardo Bezerra will present at the virtual Oppenheimer 25th Annual Consumer Growth & E-Commerce Conference on June 10 at 9 AM ET.

Perrigo is a pure-play self-care company operating primarily in North America and Europe, specializing in over-the-counter (OTC) healthcare products. The company's business model combines store brand private label offerings with branded products including Opill®, Mederma®, Compeed®, EllaOne®, and Solpadeine®.

Perrigo (PRGO) reported Q1 2025 financial results showing mixed performance. Net sales declined 3.5% to $1.04 billion, primarily due to divested businesses and currency impacts. Despite the sales decline, the company demonstrated significant profitability improvements with adjusted operating income increasing 57.6% to $147 million and adjusted EPS growing 106.9% to $0.60. The company's infant formula business showed strong recovery with 16% growth in the Nutrition category. Gross margins expanded substantially, with adjusted gross margin increasing 440 basis points to 41.0%. Due to macroeconomic uncertainty, Perrigo widened its 2025 net sales growth outlook to 0-3% from 1-3%, but reaffirmed other financial targets, including adjusted EPS guidance. The company's 'Project Energize' efficiency program has achieved approximately $159 million in gross annual savings with $20 million reinvested.

Perrigo, a leading global provider of Consumer Self-Care Products, has announced its latest quarterly dividend of $0.290 per share. The dividend will be paid on June 17, 2025, to shareholders of record as of May 30, 2025.

As a prominent provider of Consumer Self-Care Products and over-the-counter (OTC) health and wellness solutions, Perrigo focuses on empowering consumers to proactively prevent or treat self-manageable conditions. The company, listed on the NYSE under the symbol PRGO, maintains its commitment to shareholder returns through consistent dividend payments.

The press release includes standard forward-looking statements disclaimers and directs interested parties to review the company's SEC filings for detailed information about business conditions, risks, and material trends.

Perrigo (NYSE: PRGO), a leading provider of Consumer Self-Care Products, has announced it will release its first quarter 2025 financial results on Wednesday, May 7th, 2025. The company will host a conference call at 8:30 A.M. (EST).

Investors can access the earnings conference call via webcast through Perrigo's investor relations website or by phone. A taped replay will be available from approximately 12:00 P.M. (EST) on May 7 until midnight May 14, 2025.

Perrigo specializes in over-the-counter (OTC) health and wellness solutions, focusing on consumer self-managed preventive and treatment products.

Perrigo (NYSE: PRGO) unveiled its strategic 'Three-S' plan at its Virtual Investor Day, focusing on consumerizing, simplifying, and scaling its global self-care platform. The plan includes: Stabilizing Consumer Self-Care Americas store brand and infant formula businesses, Streamlining the global portfolio and operations, and Strengthening investments in key 'High-Grow' brands.

The company announced its fiscal year 2025 targets, including: 1-3% all-in net sales growth, 2.5-4.5% organic net sales growth, ~40% adjusted gross margin, and adjusted EPS of $2.90-$3.10 (13-21% growth). For fiscal years 2025-2027, Perrigo targets organic net sales CAGR of 2.5-4.5%, adjusted gross margin expansion of 200-400 basis points, and net leverage reduction to less than 3x adjusted EBITDA by 2027.

Perrigo (PRGO) reported Q4 2024 financial results with net sales of $1.14 billion, declining 1.6% year-over-year, while organic growth was 0.7%. The company delivered fiscal year 2024 adjusted EPS of $2.57, meeting guidance expectations, despite reporting a loss of $(1.17) per share.

Q4 highlights include 17% growth in infant formula sales and expansion of adjusted operating margin by 260 basis points to 17.0%. The Consumer Self-Care Americas (CSCA) segment reported flat sales at $744 million, while Consumer Self-Care International (CSCI) saw a 4.5% decline to $394 million.

The company's Project Energize initiative achieved gross annual savings of $139 million in 2024, with $17 million reinvested. The program is expected to deliver annualized pre-tax savings of $140-170 million by 2026. Notably, Perrigo's Wisconsin infant formula facility received a 'No Action Indicated' status from the FDA, marking significant improvement from its previous status.

Perrigo (NYSE: PRGO), a leading provider of Consumer Self-Care Products, has announced its participation in the UBS 2025 Global Consumer and Retail Conference. President and CEO Patrick Lockwood-Taylor and CFO Eduardo Bezerra will present on Wednesday, March 12 at 10 AM ET in New York City.

The presentation will be accessible via webcast on Perrigo's investor relations website. Perrigo specializes in over-the-counter (OTC) health and wellness solutions, focusing on empowering consumers with self-managed healthcare options.

The company has noted that their conference presentation will include forward-looking statements, subject to risks and uncertainties that may cause actual results to differ from current projections. Interested parties are encouraged to review Perrigo's SEC filings for detailed risk factors and business conditions.